Payment overview · 2025
General Payments
$853.59
32 reported records · 13 companies
Healthcare provider profile · identity verified
Michael Katiraie, DO
Allopathic & Osteopathic Physicians|Family Medicine · LOS ANGELES, CA · NPI 1730617994
Verified facts
What the public records show
CMS Open Payments records show Michael Katiraie, DO received $853.59 in general payments during 2025 across 32 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Linzess, Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 768 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 300 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $219.44 | 25.7% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $106.49 | 12.5% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $78.35 | 9.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.72 | 8.9% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $71.88 | 8.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.29 | 7.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.50 | 5.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.77 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.21 | 4.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.07 | 3.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $30.77 | 3.6% | 2 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $29.91 | 3.5% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $23.19 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $722.60 | 30 |
| Education | $130.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $106.49 | 5 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $96.05 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $78.35 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $71.88 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.83 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.81 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.81 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.50 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.50 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $37.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.21 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $34.90 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $32.07 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $30.77 | 2 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $29.91 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $29.91 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 57 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
768 | 90 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
300 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1407 | 298 |
| Amlodipine Besylate | Amlodipine Besylate | 1013 | 217 |
| Eliquis | Apixaban | 768 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 564 | 112 |
| Donepezil Hcl | Donepezil Hcl | 536 | 108 |
| Gabapentin | Gabapentin | 502 | 101 |
| Metformin Hcl | Metformin Hcl | 492 | 107 |
| Losartan Potassium | Losartan Potassium | 433 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 418 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 405 | 101 |
| Lisinopril | Lisinopril | 395 | 85 |
| Mirtazapine | Mirtazapine | 387 | 89 |
| Furosemide | Furosemide | 380 | 93 |
| Divalproex Sodium | Divalproex Sodium | 367 | 75 |
| Famotidine | Famotidine | 365 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 311 | 71 |
| Memantine Hcl | Memantine Hcl | 310 | 57 |
| Jardiance | Empagliflozin | 300 | 49 |
| Carvedilol | Carvedilol | 291 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 278 | 65 |
| Quetiapine Fumarate | Quetiapine Fumarate | 275 | 64 |
| Hydralazine Hcl | Hydralazine Hcl | 224 | 71 |
| Levetiracetam | Levetiracetam | 222 | 38 |
| Risperidone | Risperidone | 214 | 54 |
| Olanzapine | Olanzapine | 205 | 38 |
| Humulin R | Insulin Regular, Human | 181 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 178 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 165 | 47 |
| Trazodone Hcl | Trazodone Hcl | 165 | 48 |
| Lactulose | Lactulose | 164 | 52 |
| Sertraline Hcl | Sertraline Hcl | 161 | 35 |
| Omeprazole | Omeprazole | 155 | 39 |
| Potassium Chloride | Potassium Chloride | 152 | 41 |
| Januvia | Sitagliptin Phosphate | 148 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 40 |
| Entresto | Sacubitril/Valsartan | 124 | 17 |
| Latanoprost | Latanoprost | 117 | 31 |
| Allopurinol | Allopurinol | 116 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 34 |
| Spironolactone | Spironolactone | 105 | 23 |
| Finasteride | Finasteride | 100 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 93 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 91 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 91 | 42 |
| Clonidine Hcl | Clonidine Hcl | 89 | 37 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 88 | 42 |
| Oxcarbazepine | Oxcarbazepine | 86 | 15 |
| Simvastatin | Simvastatin | 86 | 22 |
| Xarelto | Rivaroxaban | 83 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 18 |
| Rivastigmine | Rivastigmine Tartrate | 79 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 21 |
| Nifedipine Er | Nifedipine | 77 | 17 |
| Topiramate | Topiramate | 77 | 14 |
| Glipizide | Glipizide | 75 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 47 |
| Buspirone Hcl | Buspirone Hcl | 71 | 20 |
| Propranolol Hcl | Propranolol Hcl | 71 | 15 |
| Lorazepam | Lorazepam | 70 | 33 |
| Sodium Chloride | 0.9 % Sodium Chloride | 70 | 38 |
| Alendronate Sodium | Alendronate Sodium | 68 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 68 | 11 |
| Ibuprofen | Ibuprofen | 68 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 67 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 19 |
| Megestrol Acetate | Megestrol Acetate | 67 | 27 |
| Albuterol Sulfate | Albuterol Sulfate | 63 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 36 |
| Baclofen | Baclofen | 59 | 18 |
| Benazepril Hcl | Benazepril Hcl | 59 | 13 |
| Linzess | Linaclotide | 57 | 16 |
| Aripiprazole | Aripiprazole | 56 | 13 |
| Tradjenta | Linagliptin | 56 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 56 | 13 |
| Montelukast Sodium | Montelukast Sodium | 55 | 17 |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 53 | 15 |
| Farxiga | Dapagliflozin Propanediol | 51 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 51 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 49 | suppressed |
| Valsartan | Valsartan | 49 | 11 |
| Atenolol | Atenolol | 48 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 46 | 14 |
| Novolin R | Insulin Regular, Human | 46 | suppressed |
| Brilinta | Ticagrelor | 45 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 45 | 18 |
| Steglatro | Ertugliflozin Pidolate | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 45 | 21 |
| Azithromycin | Azithromycin | 44 | 39 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | 16 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 43 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 17 |
| Lidocaine | Lidocaine | 42 | 13 |
| Bethanechol Chloride | Bethanechol Chloride | 41 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 35 |
| Brimonidine Tartrate | Brimonidine Tartrate | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 24 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Meloxicam | Meloxicam | 36 | 12 |
| Alogliptin | Alogliptin Benzoate | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 34 | 14 |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 34 | suppressed |
| Naproxen | Naproxen | 34 | 12 |
| Prednisone | Prednisone | 34 | 12 |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Humalog | Insulin Lispro | 33 | 13 |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Scopolamine | Scopolamine | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | 11 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Constulose | Lactulose | 30 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Cyclosporine | Cyclosporine | 29 | 12 |
| Dutasteride | Dutasteride | 29 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Restasis | Cyclosporine | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | 11 |
| Promethazine Hcl | Promethazine Hcl | 28 | 23 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 27 | suppressed |
| Lubiprostone | Lubiprostone | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Budesonide | Budesonide | 26 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 25 | suppressed |
| Enulose | Lactulose | 25 | 11 |
| Olanzapine Odt | Olanzapine | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 23 | 20 |
| Eplerenone | Eplerenone | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 22 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | 14 |
| Theophylline Er | Theophylline Anhydrous | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Prolia | Denosumab | 19 | 13 |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Haloperidol | Haloperidol | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Glucagon Emergency Kit | Glucagon Hcl | 17 | suppressed |
| Nystop | Nystatin | 17 | 13 |
| Rhopressa | Netarsudil Mesylate | 17 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Glucagon Emergency Kit | Glucagon | 16 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 14 | suppressed |
| Methazolamide | Methazolamide | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 12 |
| Sevelamer Hcl | Sevelamer Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Clonazepam | Clonazepam | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Nateglinide | Nateglinide | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | 11 |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $853.59 · 32 records | Teva Pharmaceuticals USA, Inc. | AFREZZA, AUSTEDO XR, CAPLYTA, COBENFY, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, INGREZZA, KISUNLA, Kerendia, LINZESS, MOUNJARO, OTEZLA, QULIPTA, REPATHA, REXULTI, REZDIFFRA, UBRELVY, UZEDY, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error